Adverse reactions of brigatinib/brigatinib

Brigatinib/Brigatinib (Brigatinib) is effective in the treatment of patients with ALK-positive non-small cell lung cancer who have previously received treatment with the ALK inhibitor crizotinib or who have not received treatment with an ALK inhibitor. The safety profile of brigatinib is considered manageable once appropriate measures are taken to control the potentially serious side effects of lung disease.

In clinical studies of brigatinib, the most common adverse reactions included hyperglycemia (high blood sugar levels), hyperinsulinemia (high blood insulin levels), anemia (low red blood cell count), nausea, low white blood cell count (including white blood cells called lymphocytes) decreased levels), diarrhea, fatigue, cough, headache, hypophosphatemia (low phosphate levels in the blood), rash, vomiting, difficulty breathing, high blood pressure, and signs indicating increased liver (ALT and AST and alkaline phosphatase levels), Abnormal blood test results for the pancreas (elevated lipase and amylase), muscle function (elevated CPK), or blood coagulation (elevated APTT); alsointerstitial lung disease/pneumonia span>, hypertension, bradycardia, visual impairment, elevated creatine phosphokinase, elevated pancreatic enzyme, hepatotoxicity, hyperglycemia, photosensitivity, embryo-fetal toxicity and other warnings and precautions.

In short, although brigatinib has good efficacy in the treatment of non-small cell lung cancer, patients still need to pay attention to possible adverse reactions during use. During the medication process, patients should pay close attention to their physical condition and promptly report any symptoms of discomfort to the doctor so that the doctor can adjust the treatment plan in a timely manner to ensure the smooth progress of the treatment.